226 related articles for article (PubMed ID: 32172359)
1. Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.
Kucine N
Curr Hematol Malig Rep; 2020 Apr; 15(2):141-148. PubMed ID: 32172359
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR
Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540
[TBL] [Abstract][Full Text] [Related]
3. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
[TBL] [Abstract][Full Text] [Related]
6. Myeloproliferative neoplasms in adolescents and young adults.
Amerikanou R; Lambert J; Alimam S
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101374. PubMed ID: 36333071
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and management of children, adolescents, and young adults with Philadelphia chromosome-negative myeloproliferative neoplasms].
Sugimoto Y
Rinsho Ketsueki; 2023; 64(10):1314-1325. PubMed ID: 37914247
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative Neoplasms: A Contemporary Review.
Tefferi A; Pardanani A
JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
[TBL] [Abstract][Full Text] [Related]
9. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
Shrestha R; Giri S; Armitage JO; Bhatt VR
Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
Bao M; Zhang M; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
Acta Haematol; 2023; 146(4):293-306. PubMed ID: 36812897
[TBL] [Abstract][Full Text] [Related]
11. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
12. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.
England JT; Szuber N; Sirhan S; Dunne T; Cerquozzi S; Hill M; Villeneuve PJA; Ho JM; Sadikovic B; Bhai P; Krishnan N; Dowhanik S; Hillis C; Capo-Chichi JM; Tsui H; Cheung V; Gauthier K; Sibai H; Davidson MB; Bankar A; Kotchetkov R; Gupta V; Maze D
Leukemia; 2024 Mar; 38(3):570-578. PubMed ID: 38321107
[TBL] [Abstract][Full Text] [Related]
13. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Sobas M; Kiladjian JJ; Beauverd Y; Curto-Garcia N; Sadjadian P; Shih LY; Devos T; Krochmalczyk D; Galli S; Bieniaszewska M; Seferynska I; McMullin MF; Armatys A; Spalek A; Waclaw J; Zdrenghea M; Legros L; Girodon F; Lewandowski K; Angona Figueras A; Samuelsson J; Abuin Blanco A; Cony-Makhoul P; Collins A; James C; Kusec R; Lauermannova M; Noya MS; Skowronek M; Szukalski L; Szmigielska-Kaplon A; Wondergem M; Dudchenko I; Gora Tybor J; Laribi K; Kulikowska de Nalecz A; Demory JL; Le Du K; Zweegman S; Besses Raebel C; Skoda R; Giraudier S; Griesshammer M; Harrison CN; Ianotto JC
Blood Adv; 2022 Sep; 6(17):5171-5183. PubMed ID: 35802458
[TBL] [Abstract][Full Text] [Related]
14. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
15. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
16. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
[TBL] [Abstract][Full Text] [Related]
17. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
18. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.
Casini A; Fontana P; Lecompte TP
J Thromb Haemost; 2013 Jul; 11(7):1215-27. PubMed ID: 23601811
[TBL] [Abstract][Full Text] [Related]
20. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]